ARWR Arrowhead Pharmaceuticals
- 22.120
- +0.250+1.14%
- 21.750
- -0.370-1.67%
Arrowhead Pharmaceuticals News
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it will host a webcast and conference call on May 9, 2024, at 4:30 p.m. ET to discuss its financial results for the fiscal second quarter ended March
Express News | Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of Aro-Cfb for Treatment of Complement Mediated Kidney Disease
Express News | Arrowhead Pharmaceuticals Has Dosed The First Subjects In A Phase 1/2A Trial Of ARO-CFB, The Company's Investigational RNA Interference Therapeutic, In Up To 66 Healthy Volunteers And Patients With Complement Mediated Kidney Disease
Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares May Have Run Too Fast Too Soon
With a price-to-sales (or "P/S") ratio of 15.2x Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) may be sending bearish signals at the moment, given that almost half of all Biotechs companies in the Unit
Hepion Ends Phase 2 Study for NASH Drug Due to Cash Restraints
Express News | Turnstone Biologics Appoints William Waddill to Its Board of Directors
Wolfe Upgrades Ionis to Outperform, Cites Upcoming Catalysts
Buy Rating Affirmed for Arrowhead Pharmaceuticals Following Promising Plozasiran Trial Results
Madrigal Announces US Launch of NASH/MASH Drug Rezdiffra
Arrowhead Pharmaceuticals (ARWR) Receives a Buy From Piper Sandler
Express News | Reported Sunday, Arrowhead Pharmaceuticals Announces New Phase 2 Data Of Plozasiran Published In JAMA Cardiology And Presented At ACC.24
Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented final data from the double-blind treatment period of its Phase 2 SHASTA-2 study of investigational plozasiran (formerly ARO-APOC3) in patients with severe hypertriglyceridemia (SHTG).
NetApp, Zoom Video And 2 Other Stocks Insiders Are Selling
The Nasdaq 100 closed higher by around 0.2% on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be a preplanned sale, or could indicate thei
Insider Sell: Chief Discovery/Trans Medicine James Hamilton Sells 6,000 Shares of Arrowhead ...
Arrowhead Pharmaceuticals(ARWR.US) Officer Sells US$168.18K in Common Stock
$Arrowhead Pharmaceuticals(ARWR.US)$ Officer Hamilton James C sold 6,000 shares of Common Stock on Apr 1, 2024 at an average price of $28.03 for a total value of $168.18K.Source: Announcement What is
Form 144 | Arrowhead Pharmaceuticals(ARWR.US) Officer Proposes to Sell 168.16K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 1, $Arrowhead Pharmaceuticals(ARWR.US)$ Officer Hamilton James C intends to sell 6,000 shares of its common stock on Apr 1, with a total market value of approximately $168.
Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PASADENA, Calif.--(BUSINESS WIRE)--$arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on March 30, 2024, the Comp
The Past Three Years for Arrowhead Pharmaceuticals (NASDAQ:ARWR) Investors Has Not Been Profitable
If you love investing in stocks you're bound to buy some losers. Long term Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) shareholders know that all too well, since the share price is down considerabl
Express News | Arrowhead Pharmaceuticals Initiates Expanded Access Program For Plozasiran
Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data
Arrowhead is committed to bringing new investigational medicines to patients with serious diseases as quickly and efficiently as possible.
Analysis
Price Target
No Data
